Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ansa is a combination product formulated as a sachet containing three active pharmaceutical ingredients: Vaccinium macrocarpon (commonly known as cranberry), Saraca indica, and Cimicifuga racemosa. It has been developed primarily for the prevention and treatment of uncomplicated urinary tract infections (UTIs) in females. The rationale behind this combination is to leverage the anti-adhesive properties of cranberry against uropathogens like Escherichia coli, while Saraca indica and Cimicifuga racemosa are included for their potential to normalize hormonal levels, which may help reduce recurrent UTIs especially in peri-menopausal and menopausal women. The product is being evaluated in clinical trials for its efficacy compared to other UTI preventive therapies[1][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ansa.